Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 16/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 12/20 | 0.41 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiazofurin SCHEMBL4453888 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL13109276 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL2883657 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23848843 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL4287 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL7169632 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL1651851 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL23264566 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL2883659 | 0.88 | PYGL (0.53) | PYGLIMPDH2IMPDH1 | |
| Tiazofurin SCHEMBL27702607 | 0.79 | PYGL (0.43) | PYGLIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | NORTHWESTERN UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | NORTHWESTERN UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | IMPDH1, IMPDH2, AMPD3 | PYGL 1653/4885IMPDH2 2/4885IMPDH1 1/4885 |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | IMPDH1, IMPDH2, AMPD3 | PYGL 1653/4885IMPDH2 2/4885IMPDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.